Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03663504
Other study ID # OTT 18-03
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date October 23, 2018
Est. completion date December 2026

Study information

Verified date April 2024
Source Ottawa Hospital Research Institute
Contact Lisa Vandermeer
Phone 613-737-7700
Email lvandermeer@toh.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The REaCT NSQIP will compare oral antibiotics vs. no antibiotics, which are two standards of care treatments for preoperative preparation of the bowel prior to colorectal surgery


Description:

The divergence of clinical practice guidelines, in addition to observation from the large North American retrospective studies, suggest that surgeons and centers have not established a standard of care for the preoperative preparation of the bowel prior to colorectal surgery. Specifically, some centers are employing no preparation, others are administering a mechanical bowel preparation (MBP) and oral antibiotics and still others are using oral antibiotics alone. Recently, the Canadian Society of Colorectal Surgeons was unable to come to a consensus when attempting to update their preoperative guidelines because of the lack of agreement on best practice (personal communication). This is an important yet controversial topic in colorectal surgery and a clinical trial comparing two standard of care therapies will impact current practice in Canada. The REaCT-NSQIP study compares post-operative surgical infectious complications, length of stay, incidence of C. difficile rates, patient quality of life and cost-effectiveness in patients undergoing elective colorectal surgery with either no preparation or oral antibiotics. Data will be collected from the National Surgical Quality Improvement Program (NSQIP) and from patient quality of life questionnaires preoperatively and 30 days postoperatively In this study, it is hypothesized that it is the oral antibiotics, and not the MBP, that is responsible for the reduction in postoperative infectious surgical complications (deep or superficial surgical site infection (SSI)) in patients undergoing elective colorectal resections. This improvement in postoperative infectious complications is not anticipated to result in a clinically significant increase in postoperative C. difficile infections or antibiotic resistant hospital-acquired infections.


Recruitment information / eligibility

Status Recruiting
Enrollment 432
Est. completion date December 2026
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients undergoing elective, non-emergency colon, resection surgery or abdominal perineal resection and no other requirements exists for a mechanical bowel preparation (as determined by the operating surgeon) - 18 years of age or older - Able to provide oral consent Exclusion Criteria: - Contraindication to the oral antibiotics, including allergies or adverse reactions to either metronidazole or neomycin - Undergoing a rectal resection with a planned anastomosis (these patients will all receive MBP) - Emergency surgery where no opportunity to administer preoperative oral antibiotics exists - Requirement for a MBP (i.e. rectal resection with pelvic anastomosis, intraoperative colonoscopy, or at the discretion of the treating surgeon

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No Preparation
No preparation before surgery
Drug:
Neomycin and Flagyl
Oral antibiotic (Neomycin and Flagyl) taken the day before the surgery

Locations

Country Name City State
Canada The Queen Elizabeth II Health Sciences Centre Halifax Nova Scotia
Canada Queensway Carleton Hospital Ottawa Ontario
Canada The Ottawa Hospital Cancer Centre Ottawa Ontario
Canada Renfrew Victoria Hospital Renfrew Ontario
Canada Sunnybrook Health Sciences Centre Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
Ottawa Hospital Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post-Operative Surgical Infection Complication To evaluate that use of oral antibiotics (neomycin and flagyl), administered the day prior to elective colonic resection is associated with a significant reduction in postoperative (within 30 days) surgical infectious complications (superficial and deep space infections). 30 days
Secondary Grade III-IV Postoperative Surgical Site Infectious Complication To evaluate the effects of oral antibiotics on Grade III-IV (Clavien-Dindo classification) postoperative surgical site infectious complication (at 30 days). 30 days
Secondary Postoperative Infections Complications To evaluate the effects of oral antibiotics on postoperative infections complications classified as deep SSI, superficial SSI or non-SSI infectious complications (i.e. urinary tract infection, pneumonia, at 30 days). 30 days
Secondary Overall Postoperative Complication Rate To evaluate the effects of oral antibiotics on overall postoperative complication rate (at 30 days). 30 days
Secondary Postoperative Length of Stay To evaluate the effects of oral antibiotics on postoperative length of stay (LOS). Number of days spent in hospital post-operatively, average of 6 days
Secondary Incidence of Postoperative C. difficile Infections To evaluate the effects of oral antibiotics on the incidence of postoperative C. difficile infections (at 90 days). 90 days
Secondary Incidence of Antibiotics Resistant Postoperative Infectious Complications To evaluate the effects of oral antibiotics on the incidence of of antibiotics resistant postoperative infectious complications (at 30 days) 30 days
Secondary Patient Quality of Life To evaluate the effects of oral antibiotics on patient quality of life by administering the SF-36 questionnaire, undertaken preoperatively and at 30 days postoperatively. The Short Form-36 (SF-36) is a 36-item, patient reported survey that is a measure of health status and commonly used in health economics. This SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. A low score denounces a worse outcome compared to a higher score that denounces a better outcome. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. 30 days
Secondary Direct Estimation of Health Utility Values To evaluate the effects of oral antibiotics on patient quality of life by administering the EQ-5D-5L questionnaire, undertaken preoperatively and 30 days postoperatively. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) questionnaire consists of two sections; the EQ-5D-5L descriptive system and the EQ Visual Analogue scale. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). There are 5 levels associated with it; no problems, slight problems, moderate problems, severe problems and extreme problems. The scale range of 1-5 is used for the 5 dimensions in the descriptive system where 1 is the best outcome and 5 is the worst outcome. The Visual Analogue scale records the respondent's self-rated health on a vertical, visual scale with endpoints labelled 'the best health you can imagine' at the top and 'the worst health you can imagine' at the bottom. This ranges 0 being the worst outcome to 100 being the best outcome. 30 days
Secondary Incremental Cost-Effectiveness Ratio To evaluate the effects of antibiotics on the incremental cost-effectiveness ratio Through to study completion, an average of 2 years